FAS-MEDIATED CYTOTOXICITY AN IMMUNOEFFECTOR OR IMMUNOREGULATORY PATHWAY IN T CELL-MEDIATED IMMUNE RESPONSES?
CHRISTIAN P. LARSEN(Emory University), Thomas C. Pearson(Emory Healthcare), Shannon C. Ritchie(Emory University), Rose Hendrix(Emory Healthcare), Diane Z. Alexander(Emory University)
Cited by 83
Related Papers
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Heterologous immunity provides a potent barrier to transplantation tolerance
|Journal of Clinical Investigation|2003|571
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
|American Journal of Transplantation|2010|566